Literature DB >> 1647421

Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.

J Huskinson-Mark1, F G Araujo, J S Remington.   

Abstract

The cyst form of Toxoplasma gondii has been implicated as a cause of recrudescence of the latent infection in congenitally infected patients and in the immunocompromised host. A method was developed to evaluate the effect of drugs on the cyst form of the parasite and used to evaluate a variety of therapeutic agents. The most active compounds against the cyst form in vitro were arprinocid-N-oxide, azithromycin, and the hydroxynaphthoquinone 566C80.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1647421     DOI： 10.1093/infdis/164.1.170

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  39 in total

1.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.

Authors:  S K Moshkani; A Dalimi
Journal:  Vet Res Commun       Date:  2000-04       Impact factor: 2.459

3.  Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds.

Authors:  Danièle Maubon; Alexandre Bougdour; Yung-Sing Wong; Marie-Pierre Brenier-Pinchart; Aurélie Curt; Mohamed-Ali Hakimi; Hervé Pelloux
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

4.  In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.

Authors:  F G Araujo; J Huskinson-Mark; W E Gutteridge; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

5.  Reexamining Chronic Toxoplasma gondii Infection: Surprising Activity for a "Dormant" Parasite.

Authors:  Anthony P Sinai; Elizabeth A Watts; Animesh Dhara; Robert D Murphy; Matthew S Gentry; Abhijit Patwardhan
Journal:  Curr Clin Microbiol Rep       Date:  2016-10-04

6.  Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.

Authors:  R Dixon; A L Pozniak; H M Watt; P Rolan; J Posner
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Expressed sequence tag analysis of the bradyzoite stage of Toxoplasma gondii: identification of developmentally regulated genes.

Authors:  I D Manger; A Hehl; S Parmley; L D Sibley; M Marra; L Hillier; R Waterston; J C Boothroyd
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

8.  A morphological study of chronic cerebral toxoplasmosis in mice: comparison of four different strains of Toxoplasma gondii.

Authors:  D J Ferguson; J Huskinson-Mark; F G Araujo; J S Remington
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

9.  Cytokine mRNA in the central nervous system of SCID mice infected with Toxoplasma gondii: importance of T-cell-independent regulation of resistance to T. gondii.

Authors:  C A Hunter; J S Abrams; M H Beaman; J S Remington
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

10.  Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites.

Authors:  Dion A Kevin Ii; Damaris Af Meujo; Mark T Hamann
Journal:  Expert Opin Drug Discov       Date:  2009-02       Impact factor: 6.098
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.